Understanding of the molecular determinants responsible for antagonist binding to the oxytocin receptor should provide important insights that facilitate rational design of potential therapeutic agents for the treatment of preterm labor. To study ligand/receptor interactions, we used a novel photosensitive radioiodinated antagonist of the human oxytocin receptor, d ( 
1 a neurohypophyseal nonapeptide, is among the strongest uterotonic agents known to date (1, 2) . This hormone acts on the myometrium through specific OT receptors (OTRs) that show a dramatic increase in their expression pattern immediately before parturition (3) . In mammals at term, OT-induced contractility of myometrial smooth muscle cells is triggered through an increase in the intracellular calcium level (4) . This calcium signaling pathway is dependent on coupling the OTR to both the G q/11 and G i proteins (5) . The OTR cDNA of several mammalian species has been cloned (6 -9) , and the deduced amino acid sequence confirmed that the receptor belongs to the large family of seven-helix transmembrane G protein-coupled receptors. OT is widely used in obstetrical practice to promote labor and delivery (10) . On the other hand, blockade of the OTR may provide a unique approach for treatment of preterm labor by prolonging uterine quiescence (11) (12) (13) . Therefore, much effort has been focused on the design and development of OT antagonists as potential tocolytic drugs. The utility of such OT antagonists has been demonstrated clinically by using intravenously administered 1-deamino[DTyr(Et) 2 ,Thr 4 ,Orn 8 ]vasotocin (Atosiban). This peptide antagonist has been shown to inhibit uterine contractions in women with threatened and established preterm labor (14, 15) . However, the structure/function relationships of the functional domains of the OTR and the topography of the ligand-binding sites are still poorly investigated. Such knowledge should provide valuable information on the structural requirements for antagonist binding and should be helpful for the rational design of potential therapeutic agents and for a better understanding of the molecular mechanisms leading to receptor inactivation. Agonist-binding sites of the OTR have been investigated previously by site-directed mutagenesis and three-dimensional (3D) molecular modeling (16 -18) . In parallel, a major contribution to peptide antagonist binding affinity by the upper part of transmembrane domain (TMD) VII has been demonstrated (18) .
The photoaffinity labeling technique is an essential complement to modeling and mutagenesis approaches and allows unambiguous direct determination of the ligand/receptor contact I-ZOTA, d(CH 2 ) 5 [Tyr(Me) 2 regions. So far, radiolabeled OT analogues containing a photoactivatable group at the side chain of residue 8 have been used to photolabel the OTR naturally expressed in the rat mammary gland, the guinea pig uterus, and the rabbit amnion or transfected in COS cells (recombinant porcine receptor). These studies allowed the identification of the receptor as a glycoprotein with an apparent molecular mass between 65 and 80 kDa (18 -22) . However, the precise localization of the covalent attachment of these ligands to the receptor has not been investigated.
The present study has been performed to localize accurately peptie antagonist-binding domains of the human OTR using a photoaffinity labeling approach. Based on the structure of the previously reported potent and high affinity cyclic peptide antagonist d(CH 2 ) 5 [Tyr(Me) 2 ,Thr 4 ,Orn 8 ,Tyr(3 125 I)-NH 2 9 ]vasotocin ( 125 I-OTA) (23), we have designed, synthesized, and characterized a new radiolabeled photosensitive antagonist containing an azido group on the amino acid at position 9, termed 125 I-ZOTA 2 . Because this novel radioligand displays an equivalent high affinity for the human OTR and the structurally related human V 1a arginine-vasopressin (AVP) receptor, we decided to conduct a comparative photolabeling study on both receptors. Because we already accumulated a large amount of data on linear and cyclic peptide antagonist-binding sites of the V 1a receptor from direct receptor photoaffinity labeling experiments (24 -26) as well as from site-directed mutagenesis and 3D molecular modeling studies (27-29; for review, see Ref. 30 ), we therefore hypothesized that this dual comparative investigation should further increase our understanding of OTR/antagonist interactions. We describe here the photolabeling of the human OTR and the human V 1a AVP receptor with 125 I-ZOTA and their proteolytic fragmentation using CNBr and Lys-C and Arg-C endoproteinases. Compilation of all the data shows that covalent attachment is restricted to three residues, Leu 114 -Val
115
-Lys 116 , in the upper part of the OTR TMD III. Interestingly, the photolabeled region is equivalent in the V 1a receptor.
EXPERIMENTAL PROCEDURES
Radioiodination and Azidation of the Antagonist Probe-The detailed procedure of radioiodination and azidation leading to 125 I-ZOTA has been described elsewhere. 2 Briefly, a strategy consisting of the solid-phase synthesis of the precursor nonapeptide d(CH 2 ) 5 125 I-ZOTA was purified by HPLC, and its specific activity was 2200 Ci/mmol. The corresponding nonradiolabeled iodinated peptide, termed I-ZOTA, was also synthesized and purified.
Cell Culture, Receptor Expression, and Membrane Preparation-The human V 1a and OTR cDNA clones were generous gifts of Drs. Thibonnier (31) and Kimura (6) , respectively. The procedure of CHO cell transfection and stable cell line establishment have been described previously (25, 26) . CHO cells stably expressing either the human OT, V 1a , V 2 , or V 1b receptor were cultured in Petri dishes in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal calf serum, 4 mM L-glutamine, 500 units/ml penicillin and streptomycin each, and 0.25 g/ml amphotericin B in an environment containing 95% air and 5% CO 2 at 37°C. Depending on the experiment to be conducted, cells were treated overnight with 5 mM sodium butyrate to increase receptor expression (32, 33) . As already published, this treatment does not modify the pharmacological properties of the receptors (17, 25, 26) . Membranes were prepared as already described (27) . In short, cells were washed twice in phosphate-buffered saline without  Ca  2ϩ and Mg   2ϩ , Polytron-homogenized in lysis buffer (15 mM Tris-HCl, pH 7.4; 2 mM MgCl 2 ; 0.3 mM EDTA) and centrifuged at 800 ϫ g for 5 min at 4°C. Supernatants were recovered and centrifuged at 44,000 ϫ g for 20 min at 4°C. Pellets were washed in Buffer A (50 mM Tris-HCl, pH 7.4; 5 mM MgCl 2 ) and centrifuged at 44,000 ϫ g for 20 min at 4°C. Membranes were suspended in a small volume of Buffer A, and the protein content was determined by the Bradford method (Bio-Rad) using bovine serum albumin (BSA) as the standard. Aliquots of membranes were used immediately for binding assays and photolabeling experiments or stored at Ϫ80°C.
Radioligand 3 H]AVP (Ϸ1-2 nM) as the radioligand. The concentrations of the unlabeled ligands varied from 1 pM to 10 M. In saturation and competition experiments, depending on the radiolabeled peptide, nonspecific binding was determined by adding unlabeled AVP (10 M), I-OTA (400 nM), or I-ZOTA (400 nM). Bound and free radioactivity was separated by filtration over Whatman GF/C filters presoaked in a 10 mg/ml BSA solution for 3-4 h. The ligand binding data were analyzed by nonlinear least squares regression using the computer program Ligand (34) .
Inositol Phosphate Assays-The antagonist activity of I-ZOTA was determined by measuring inhibition of OT-stimulated inositol phosphate (IP) accumulation as described previously (25, 26) . Briefly, CHO cells expressing the human OT receptor were plated and grown in six-well dishes for 48 h in Dulbecco's modified Eagle's medium-supplemented medium and then labeled for 24 h with myo [2- 3 H]inositol (10 -20 Ci/mmol, PerkinElmer Life Sciences) at a final concentration of 1 Ci/ml in a serum-free, inositol-free medium (Life Technologies, Inc.). Cells were washed twice with phosphate-buffered saline medium, equilibrated at 37°C in phosphate-buffered saline for 1 h, and then incubated for 10 min in phosphate-buffered saline supplemented with 10 mM LiCl in the presence or absence of increasing concentrations of I-ZOTA (from 10 Ϫ12 to 10 Ϫ6 M). CHO cells were stimulated for 15 min with 10 Ϫ8 M OT (a concentration close to the K act value determined in CHO cells). The reaction was stopped by adding ice-cold perchloric acid. After neutralizing the samples, total IPs were extracted and purified by anion-exchange chromatography (Dowex AG 1-X8 column, formate form, 200 -400 mesh, Bio-Rad). For each sample, a fraction containing total IPs was collected and counted. K inact constants were calculated as 50 is the concentration of antagonist leading to 50% inhibition, [OT] was kept at 10 nM, and K act is the concentration of OT inducing half-maximum accumulation of IPs (K act ϭ 12.9 nM in CHO cells expressing the wild-type human OT receptor (17) ).
Photoaffinity Labeling of the Receptors with 125 I-ZOTA-Photoaffinity labeling experiments were carried out as described previously with the V 1a receptor photoactivatable antagonists (25, 26) . In short, membranes expressing OTR or V 1a (500 g) were resuspended in 4 ml of binding Buffer A containing BSA (0.5 mg/ml) in Corex glass tubes. Then 125 I-ZOTA (Ϸ1-2 nM) was added to the membranes, and samples were incubated at 30°C for 1 or 3 h in the dark with or without OT or AVP (10 M) to determine specific labeling. Membranes were separated from unbound ligand by washing with Buffer A without BSA and two subsequent centrifugation steps (20 min, 44,000 ϫ g, 4°C). The final pellet was resuspended in 1 ml of Buffer A and photolyzed with ultraviolet light (254 nm) for 1-5 min on ice. After photolysis, membranes were washed twice (1 ml of Buffer A) and finally resuspended in Laemmli buffer (35) . Samples were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) using 1-mm-thick 12% acrylamide gels. Gels were fixed in glacial acetic acid:methanol:Me 2 SO:water (16:40:2:42), dried, and exposed to Kodak XAR-5 films at Ϫ80°C. The assessment of covalent binding yield was performed after gel drying. Gels were cut into slices, and the radioactive content in each slice was determined. Covalent binding was determined by calculating the amount (in picomoles) of labeled receptors as a percentage of the total number of receptors expressed in the membrane preparation.
Electroelution of the Photolabeled OT and V 1a Receptors-Photolabeled membranes were first subjected to SDS-PAGE using 12% acrylamide gels as described above. After electrophoresis, the labeled bands were excised from the preparative gel, and the human OTR and V 1a were electroeluted using an electroeluter (model 422, Bio-Rad) in Trisglycine running buffer (25 mM Tris; 182 mM glycine, pH 8.3; 0.1% SDS). Samples containing electroeluted OTR and V 1a were washed and concentrated using Microcon-50 or Microcon-30, respectively (Amicon). Fragmentation with CNBr and Lys-C/Arg-C endoprotease digestions were performed using these concentrated samples.
Deglycosylation of the Photolabeled OT Receptors with N-Glycosidase F-The photolabeled CHO membranes (100 g) or electroeluted OTR was resuspended in deglycosylation buffer (100 mM Na 2 HPO 4 / NaH 2 PO 4 , pH 8.0; 10 mM EDTA; 1% digitonin; 1% 2-mercaptoethanol; 5 g/ml leupeptin; 0.1% SDS) and digested with 2 units of N-glycosidase F (Roche Molecular Biochemicals) for 2 days at 37°C. Deglycosylated receptors were analyzed by SDS-PAGE using 12% gels.
Chemical and Enzymatic Cleavage of the Photolabeled OT and V 1a Receptors-The electroeluted receptors were first subjected to single digestion with CNBr or Lys-C/Arg-C endoproteinase. CNBr, Lys-C, and Arg-C cleave proteins specifically at the carboxyl terminus of methionine, lysine, and arginine residues, respectively. Double digestions were also performed (first digestion with Arg-C followed by a second digestion with CNBr). CNBr cleavage of the electroeluted OTR and V 1a was carried out in 100 l of 70% (v/v) formic acid containing a few crystals of CNBr. The mixture was incubated in the dark for 24 h at room temperature under argon and was then stopped by adding 500 l of water. The sample volume was reduced under vacuum, and formic acid was removed by solvent exchange with water. Endoproteinase Lys-C (sequencing grade from Lysobacter enzymogenes, Roche Molecular Biochemicals) was used at 0.2 g/assay in a final volume of 50 l. The digestion was performed in 25 mM Tris-HCl, pH 8.5; 1 mM EDTA; 0.1% SDS at 37°C for 16 -24 h and stopped by addition of Laemmli buffer. Endoproteinase Arg-C (sequencing grade from Clostridium histolyticum, Roche Molecular Biochemicals) was used at 0.5 g/assay for 24 h at 37°C in a final volume of 50 l of 0.1 M Tris-HCl, pH 7.6; 10 mM CaCl 2 . To perform double fragmentations, the Arg-C digestion reaction was dried under vacuum. The pellet was resuspended in 100 l of 70% (v/v) formic acid, and CNBr cleavage was performed as indicated above. Results of cleavage were analyzed by a Tricine discontinuous SDS-PAGE system (10 -16.5% acrylamide gels) applied to the separation of small molecular mass species (36) . Gels were fixed in glacial acetic acid:methanol:Me 2 SO:water (10:50:2:38), dried, and exposed to Kodak XAR-5 films at Ϫ80°C. The molecular masses of radiolabeled receptor fragments were determined using a range of low molecular mass markers (Rainbow TM colored protein, Amersham Pharmacia Biotech).
Site-directed Mutagenesis of the Human OT and V 1a
ReceptorsPoint mutation M78A, M123A, M296A, M315A, or M330A was introduced in the human OTR cDNA sequence using the QuickChange site-directed mutagenesis kit (Stratagene). The replacement of methionine residues corresponding to potential CNBr cleavage sites by alanine residues was directly performed on the eukaryotic expression vector pCMV (37) and verified by direct dideoxynucleotide sequencing (T7 Sequencing TM kit, Amersham Pharmacia Biotech). The method used for the construction of the human V 1a receptor mutant K128A has been reported elsewhere (26, 29) . All the mutant receptors were transiently expressed in CHO cells by electroporation as published previously (27) . For all mutated receptors, cell membrane preparations, receptor photolabeling, and fragmentation experiments were conducted as described above.
RESULTS

Binding and Antagonistic Properties of the New Photoactivatable
Ligand-Pharmacological and functional properties of the wild-type human OTR and AVP V 1a receptor stably expressed in CHO cells have been published previously (17, 26, 27) . The affinity of 125 I-ZOTA, which differs from the OT antagonist 125 I-OTA (23) only by replacement of the hydroxyl group on Tyr 9 with a photosensitive azido group (see Fig. 1 ), was first directly determined for the human OTR by saturation binding experiments. As reported in Table I , the radioiodinated peptide exhibited a high affinity for OTR in the range of that measured for 125 I-OTA (K d ϭ 0.25 nM versus 0.18 nM). Like 125 I-OTA (see Table I ), the photoactivatable peptide is indeed nonselective for the OTR, displaying a very similar K d binding value for the human V 1a AVP receptor (0.45 nM). By doing competition binding experiments using [ 3 H]AVP as the radioligand, the affinity (K i ) of the I-ZOTA was also calculated for the four human AVP/OT receptor subtypes expressed in CHO cells. The results obtained are reported in Table I and confirmed lack of selectivity between the OTR and the V 1a . In CHO cells expressing the human OTR, the photoactivatable peptide I-ZOTA inhibited the IP accumulation induced by 10 nM OT in a concentration-dependent manner (data not shown). The K inact calculated from experimental IC 50 values was 0.15 Ϯ 0.02 nM (n ϭ 4), a value in agreement with the K d determined in binding experiments. Moreover, no partial agonistic activity of I-ZOTA was detected. In conclusion, the photosensitive cyclic peptide 125 I-ZOTA is a potent antagonist for the human OTR, displays equivalent high affinity for human OT and V 1a receptors, and thus constitutes a valuable tool to map peptide-binding domains of both receptors.
Photoaffinity Labeling of the Human OT and V 1a ReceptorsPhotoaffinity labeling of the human wild-type OT and V 1a receptors was directly performed on CHO cell membrane preparations. First, after incubating the photoactivatable ligand 125 I-ZOTA with the membranes, different UV irradiation times were compared to determine an optimized covalent binding yield. As shown in Fig. 2A , a 254 nm irradiation of the sample for 1 min (lane 2) led to a strong labeling of the receptor and a covalent binding yield, measured as the fraction of specifically bound radioactivity recovered in the labeled bands, reaching Ϸ7% (multiple determinations). For longer irradiation times (lanes 3-5), the covalent binding yield decreased. In all cases, 125 I-ZOTA covalently labeled a major protein band migrating at ϳ70 -75 kDa (Fig. 2, A and C, lane 3 ). An additional faint band at around 42 kDa that might represent an immature or a nonglycosylated receptor form was sometimes observable. No photolabeling was detected with nonirradiated membranes (lane 1) or in the presence of a saturating 10 M OT concentration (Fig. 2, A, lane 6, and C, lane 4) , indicating that photolabeling of the protein bands was specific for the OTR.
To determine whether the photolabeled protein at 70 -75 kDa could correspond to the native glycosylated state of the receptor expressed in the CHO cell system, the membranes were treated with N-glycosidase F before SDS-PAGE. As seen , and Asn 26 (6, 38) . The molecular mass of the smaller band migrating at 38 kDa (including the antagonist) is close to the theoretical mass of the receptor core deduced from the cDNA sequence (42.8 kDa). As reported for the guinea pig uterine OTR (21), the deglycosylation treatment led to a reaction product with a molecular mass ϳ50% of the mass of the native receptor that likely represents a final digestion product. The nature of the band obtained at 42 kDa upon photolysis remains unknown. It is interesting to note that deglycosylation of the photolabeled guinea pig receptor resulted in a protein band migrating at 38 kDa as well (21) . Taking into account insensitivity of the human OTR to the plasma membrane metalloproteinase proteolysis (18) , the upper band at 48 kDa likely represents a form of partial receptor deglycosylation rather than a proteolytic receptor fragment. Indeed, when the human OTR was transiently expressed in CHO cells or when the 70 -75-kDa band was electroeluted from preparative SDS-polyacrylamide gels, deglycosylation of the photolabeled materials always gave rise to both 38-and 48-kDa species (not shown). Taken together, the N-glycosidase F effect on the receptor protein and the lack of endoglycosidase H action (data not shown) suggest that the mature OT receptor is a glycoprotein that contains a high percentage of asparaginelinked oligosaccharides.
Using the same experimental conditions (incubation for 1 h at 30°C followed by 1 min of UV irradiation), CHO cell membranes expressing the human AVP V 1a receptor were photolabeled with 125 I-ZOTA. Two broad bands at 85-90 and 46 kDa were covalently labeled (Fig. 2C, lane 1) . Equivalent results were obtained in earlier photolabeling studies using two V 1a -selective photoactivatable peptide antagonists (25, 26) . The photolabeling of both 85-90-and 46-kDa protein bands was receptor-specific because labeling could be completely suppressed by adding 10 M AVP (Fig. 2C, lane 2) . The covalent binding efficiency of the probe to the V 1a receptor, calculated as the specifically bound radioactivity recovered in the two labeled bands, was estimated at 3% (multiple determinations). As demonstrated in two previous studies (25, 26) , the 46-kDa photolabeled band originated from a proteolytic cleavage of the entire receptor migrating at an apparent molecular mass of 85-90 kDa. Indeed, the relative abundance of the 46-kDa species (Ϸ50% in Fig. 2C, lane 1) could be significantly reduced when incubation with 125 I-ZOTA was done in the presence of ZnCl 2 and protease inhibitors for 1 h at 4°C (data not shown). As illustrated in Fig. 4 I-ZOTA, photolabeled bands were excised from preparative SDS-polyacrylamide gels, electroeluted, and subjected to chemical cleavage with CNBr or enzymatic digestion with Lys-C and Arg-C endoproteinases. Based on our present knowledge of the localization of ligand-binding sites on G protein-coupled receptors (for review, see Ref. 39 ), we have systematically excluded fragments corresponding to putative intracellular portions of the receptors as potential domains covalently bound to the ligand. For the human OTR, the unique photolabeled 70 -75-kDa band was used to perform the different fragmentation reactions (see Fig. 3 for the localization of CNBr, Lys-C, and Arg-C cleavage sites in the OTR sequence). The photoactivatable peptide itself is protected from the different degradations because it does not possess Met, Lys, or Arg residues.
The experimental OTR fragmentation patterns derived from CNBr, Lys-C, Arg-C, or Arg-C ϩ CNBr digestions are presented in Fig. 5 . For a better understanding of the results, a theoretical fragmentation map of the OTR is shown in Fig. 6 . CNBr cleavage of the photolabeled 70 -75-kDa OTR yielded three small radiolabeled bands migrating at molecular masses of Ϸ4.5, 5.5, and 6.5 kDa (Fig. 5A, lane 2) . This result restricted the site of covalent attachment to only one receptor domain, Lys 79 -Met 123 . Digestion of the photolabeled OTR with Lys-C endoproteinase yielded four fragments at molecular masses of Ϸ5, 8, 11, and 16 kDa (Fig. 5B, lane 2) . Because the smallest fragment migrated at Ϸ5 kDa, only two peptide sequences, His 80 -Lys 116 and Met 276 -Lys 306 could be covalently bound to 125 I-ZOTA. Fragment Ala 199 -Lys 226 (3.1 kDa) encompassing TMD V was eliminated as a potential candidate because of the absence of CNBr cleavage sites in this region. Digestion of the photolabeled 70 -75-kDa OTR with Arg-C endoproteinase produced four labeled bands at molecular masses of Ϸ3.4, 4, 7.8, and 10 kDa (Fig. 5C, lane 2 (Fig. 5D,  lane 3 ) generated a new fragment with a molecular mass of Ϸ3 kDa, which is slightly smaller than the 3.4 kDa obtained with Arg-C alone (Fig. 5D, lane 2) or the 4.5 kDa produced with CNBr alone (Fig. 5A, lane 2) . Among the predicted fragments resulting from a digest with Arg-C, there is only one that 6 ) and indicated that covalent binding of 125 I-ZOTA is restricted to the three amino acid residues Leu 114 -Val 115 -Lys 116 (see Fig. 3 ). We next analyzed the proteolytic fragmentation patterns of the human V 1a receptor (see Fig. 7 ), and the theoretical digestion map of this receptor is shown again in Fig. 6 . In two previous studies (25, 26) , we demonstrated that the 46-kDa photolabeled band corresponding to a truncated glycosylated V 1a receptor from Val 105 to the carboxyl-terminal end is derived from the entire 85-90-kDa photolabeled receptor and contains all the covalently bound radioactivity. Therefore, the proteolytic fragmentation of the V 1a receptor was only conducted using the material recovered in the 46-kDa protein (see Fig. 4 for the localization of CNBr, Lys-C, and Arg-C cleavage sites in the V 1a sequence). CNBr cleavage of the photoaffinity-labeled 46-kDa species yielded three labeled fragments migrating at molecular masses of Ϸ4, 5.5, and at 7.5 kDa (Fig. 7A, lane 2) . Apart from the additional 4-kDa band, the CNBr cleavage pattern was similar to the one described previously using the photoactivatable linear peptide antagonist 125 . Arg-C endoproteinase digestion of the photolabeled 46-kDa receptor yielded three labeled fragments at molecular masses of Ϸ 4, 6.5, and 10 kDa (Fig.  7C, lane 2 fragment is the best candidate, labeling of both regions could be in agreement with results obtained from the CNBr cleavage and the Lys-C digestion. To confirm this localization, successive treatment of the 46-kDa photolabeled receptor with Arg-C and CNBr was done, generating a new fragment at a molecular mass of Ϸ3 kDa (Fig. 7D, lane 2) , which is slightly smaller than the 4-kDa bands obtained with CNBr or Arg-C alone. The labeled receptor fragment at Ϸ3 kDa corresponds most likely to the Val 126 -Met 135 sequence. The identification of this fragment as the site of covalent binding for 125 I-ZOTA would be entirely consistent with the results of the CNBr, Lys-C, and Arg-C cleavages described above. Compilation of all the fragmentation patterns (see Fig. 6 ) highlighted that the covalent attachment of 125 I-ZOTA to the human V 1a receptor might also be restricted to the three amino acids these Met residues). Moreover, to eliminate the possibility that photolabeling might have occurred elsewhere in the receptor, other potential CNBr cleavage sites in TMD VI and TMD VII were also mutated (M296A, M315A, M330A; see Fig. 3 ). All mutant receptors were transiently expressed in CHO cells and photolabeled with 125 I-ZOTA. CNBr cleavage fragments obtained using radiolabeled mutant receptors were then compared with the fragments obtained with the wild-type OTR. The fragmentation patterns of M296A, M315A, and M330A mutant receptors were equivalent to that of the wild-type OTR (the three labeled fragments at Ϸ4.5, 5.5, and 6.5 kDa were recovered, data not shown), confirming that regions including TMD VI and TMD VII were not photolabeled. By contrast, as illustrated in Fig. 8 , the CNBr cleavage of both M78A and M123A mutant receptors only produced a unique major 6.5-kDa radiolabeled band (lanes 4 and 6) . The two smaller bands at 4.5 and 5.5 kDa visualized in the wild-type OTR fragmentation (lane 2) were not present anymore, confirming that the covalently bound domain of the OTR with 125 I-ZOTA is delimited by Met 78 and Met 123 residues. To confirm as well our hypothesis regarding the localization of the covalent attachment site of 125 I-ZOTA to TMD III in the human V 1a receptor, we used in this study a K128A mutant V 1a receptor (Lys 128 constitutes a potential cleavage site for Lys-C protease, see Fig. 4 ), which was constructed and described previously (26, 29) . Following expression in CHO cells and photolabeling of the mutated receptor, the corresponding 46-kDa radiolabeled fragment was digested with Lys-C, and the resulting fragmentation was compared with that obtained with the wild-type receptor. As shown in Fig. 9 , the 5-kDa band produced upon cleavage of the wild-type receptor with Lys-C endoproteinase (lane 2) was no more visible when the mutant FIG. 8 . Chemical CNBr fragmentation of photolabeled M78A and M123A mutant OTR. Photolabeling of CHO cell membranes (1 mg) expressing wild-type, mutant M78A, or mutant M123A OTR as well as preparative 12% SDS-PAGE were performed as described in the legends to Figs. 2 and 5. Radioactive material at 70 -75 kDa, corresponding to each receptor, was electroeluted, washed, and concentrated before being subjected to CNBr cleavage. Equivalent amounts of photolabeled receptors were used in each chemical cleavage assay (20,000 cpm). The radiolabeled samples, i.e. wild-type (lanes 1 and 2) , mutant M78A (lanes 3 and 4) , and mutant M123A (lanes 5 and 6) were treated (lanes 2, 4, and 6) or not (lanes 1, 3, and 5) with CNBr for 24 h in the dark at room temperature. An autoradiogram of a discontinuous 10 -16.5% dried gel exposed to Kodak XAR-5 film at Ϫ80°C for 72 h is shown. Molecular mass markers are indicated on the left. This fragmentation pattern is representative of three distinct experiments. K128A receptor was used instead (lane 4). The Lys-C fragmentation pattern yielded only the 8-and 14-kDa photolabeled fragments, confirming that covalent binding of 125 I-ZOTA to the human V 1a receptor is located in TMD III. Taken together, these results demonstrate that upon UV irradiation the cyclic peptide antagonist 125 I-ZOTA attaches covalently to both OTR and V 1a at an equivalent position in the upper part of TMD III.
DISCUSSION
It is well established that OTR is a major therapeutic target in the control of labor, thus analysis of the structure/function relationships of its functional domains, particularly the ligand binding pocket, is very important. However, relatively little information on the characterization of OTR antagonist-binding sites is currently available. In one report, the upper part of TMD VII has been demonstrated to participate in the binding of an 125 I-OTA-derived antagonist (18) . To provide further information on structural requirements for antagonist binding to the human OTR, we have undertaken a photoaffinity labeling study with a novel photoactivatable cyclic peptide ligand. The structure of I-ZOTA or that of its radiolabeled counterpart 125 I-ZOTA is based on that of I-OTA for which properties were described more than 10 years ago (23) . We have first pharmacologically and functionally characterized 125 I-ZOTA 2 (present study) and demonstrated that this OT antagonist combined high affinity, low nonspecific binding, easiness and efficiency of radioiodination, and appreciable covalent binding yield. Like 125 I-OTA (40) , 125 I-ZOTA behaved as a nonselective compound displaying equivalent high affinity for both the human OTR and the human AVP V 1a receptor. Taking advantage of this lack of selectivity, we decided to conduct a comparative photoaffinity labeling study on both receptors.
The photolabeled OTR migrated on SDS-polyacrylamide gels as a unique glycosylated broad band with an apparent molecular mass of 70 -75 kDa. The size of the human OTR is consistent with the molecular mass reported for OTRs isolated from rat mammary gland, guinea pig uterus, or rabbit amnion (19 -22) . Deglycosylation of the photolabeled OTR converted the 70 -75-kDa protein into two bands of molecular masses of Ϸ48 and 38 kDa, the latter corresponding roughly to the expected size of the peptidic core of the native receptor as described for the guinea pig OTR (21) . By contrast, using the same photolabeling conditions (incubation for 1 h at 30°C followed by 1 min of irradiation), the human V 1a receptor was degraded during incubation with the ligand, leading to two bands of molecular masses of Ϸ85-90 and 46 kDa. As described previously, the 85-90-kDa molecular species corresponds to the glycosylated native state of the receptor, whereas the 46-kDa species represented an NH 2 -terminal-truncated receptor. The latter results from a proteolytic cleavage of the 85-90-kDa band by an endogenous metalloproteinase present in the CHO membrane preparation (25, 26) . Equivalently, photolabeling of bovine kidney membranes with a tritiated photoactivatable agonist containing an arylazido group at the side chain of Lys 8 gave rise to two AVP V 2 receptor bands, a glycosylated native receptor at Ϸ58 kDa and an NH 2 -terminal-truncated form at 30 kDa (41, 42) . In that case, the proteolytic cleavage occurred between Gln 92 and Val 93 in the six-amino acid sequence FQV-LPQ located in TMD II and conserved in all neurohypophyseal hormone receptors, including the OTR. According to the authors, the proteolytic cleavage of the V 2 receptor would require a receptor conformational change dependent on the agonistic properties of the ligand (42) . We have presently shown that the human OTR is fully resistant to the proteolysis after binding of the cyclic photoactivatable antagonist, a result previously shown by others with a different photoactivatable antagonist (18, 42) . By contrast, the metalloproteinase cleavage occurred in the human V 1a receptor after incubation with 125 I-ZOTA and under the same experimental conditions. This finding is equivalent to that obtained when incubating V 1a -expressing membranes with two different photoactivatable linear peptide antagonists (25, 26) . Taken together, the present data suggest that cyclic as well as linear peptide antagonists are able to induce a conformational change leading to proteolytic cleavage in the V 1a receptor, whereas the OTR remains resistant.
Using CNBr chemical cleavage and Lys-C/Arg-C protease digestions of the photolabeled human OTR and V 1a , we demonstrated that 125 I-ZOTA covalently bound to the upper part of TMD III. This result has been confirmed using double fragmentation (CNBr followed by Arg-C protease) experiments and site-directed mutagenesis of potential CNBr or Lys-C cleavage sites in this OTR or V 1a receptor region. The covalently attached region of both receptors has been restricted to three amino acid residues only, Leu (Figs. 3 and 4) . Based on the high resolution x-ray structure of bovine rhodopsin (43) , these residues are predicted to be located at the top of TMD III. Endoproteinase Lys-C fragmentation of the photolabeled K128A mutant V 1a receptor. Photolabeling of CHO cell membranes (1 mg) expressing wild-type or mutant K128A V 1a receptors was performed as described in the legend to Fig. 7 . The corresponding 46-kDa photolabeled species were then electroeluted from a preparative 12% SDS-polyacrylamide gel and subjected to Lys-C endoproteinase digestion. Equivalent amounts of photolabeled receptors were used in each digestion assay (10,000 cpm). The radiolabeled samples, i.e. wildtype (lanes 1 and 2) or mutant K128A (lanes 3 and 4) were treated (lanes 2 and 4) or not (lanes 1 and 3) with Lys-C proteinase for 24 h at 37°C. An autoradiogram of a discontinuous 10 -16.5% dried gel exposed to Kodak XAR-5 film at Ϫ80°C for 72 h is shown. Molecular mass markers are indicated on the left. This fragmentation pattern is representative of three distinct experiments. the retinal Schiff base. As illustrated in Fig. 10 , this photoaffinity labeling study not only constituted the first direct identification of the human OTR antagonist-binding sites determined so far but also allowed us to localize a third photolabeled region in the V 1a receptor (25, 26) . Indeed, the first extracellular loop and the upper part of TMD VII of the V 1a receptor were identified as contact regions for two structurally related V 1a -selective photoactivatable linear peptide antagonists, 125 in the human V 1a , corresponding to Lys 116 in the human OTR, is well conserved throughout the AVP/OT receptor family (30) . Moreover, this residue has been shown to play a pivotal role in the binding of agonists (27, 29) , two different classes of peptide antagonists such as linear peptides (25, 26) Fig. 10) , and also the nonpeptide compound SR 49059 (29) . In the present study, the presence of Lys 128 residue in the tripeptide sequence covalently attached to the ligand is very interesting. As for V 1a -selective linear and cyclic peptide antagonists as well as for SR 49059, this Lys residue might be responsible for a direct interaction between the receptors and 125 I-ZOTA. It is very likely that the protonated amine group of Lys 128 or Lys 116 , depending on the receptor subtype, could be involved in a classical -cation interaction with the electron cloud of the phenyl ring of Phe 9 of the ligand. This kind of interaction is often encountered in protein structures (44) . Alternatively, the ammonium group of Lys could form a hydrogen bond with a carbonyl function of the peptide backbone. The predicted interaction between Lys 128 and 125 I-ZOTA is in good agreement with 3D antagonists/V 1a receptor models that we have constructed previously for V 1a -selective linear and cyclic peptide antagonists (25, 26, 29) . Moreover in the present study, we have performed the photolabeling of the K128A mutant V 1a receptor using a high concentration of 125 I-ZOTA (around 2-3 nM), but we were not able to directly measure the K d of the radioligand in saturation studies. This suggests that the affinity of the ligand was reduced and also reinforces a putative role for this residue in the binding of the ligand. As a control, we tried as well to directly measure the affinity for [ 3 H]AVP, but as already demonstrated in COS cells (29) , mutation of Lys 128 of the human V 1a receptor into an alanine significantly decreased affinity for this radioligand. The affinity of AVP for the mutant K128A was finally determined in competition studies using the V 1a -selective antagonist 125 I-HO-LVA (45), and K i was 43 Ϯ 6.8 nM (n ϭ 3). This value is in agreement with that measured in COS cells (29) . Altogether, these data magnify the role of Lys 128 (Lys 116 in OTR) and demonstrate again that this residue contributes to the overlap of agonist-and antagonist-binding sites in the human V 1a receptor binding pocket (29) . The role of Lys 128 could be compared with that of Asp 113 of cationic neurotransmitter receptors localized again in the upper part of TMD III. Substitution of this residue dramatically affects the affinity of both ammonium group-containing agonists and antagonists in the ␤-adrenergic receptor (46) .
As depicted in Fig. 10 , most of the interactions between linear or cyclic peptide antagonist ligands and the V 1a receptor (25) (26) (27) (28) (29) (30) 2 ]AVP is also equivalent to that of the hormone AVP. According to these models, AVP and its peptide antagonists, at least in the V 1a receptor, could enter this transmembrane central binding pocket and interact with overlapping binding regions. As for AVP and the three peptide antagonists, we hypothesize that 125 I-ZOTA is also able to enter this central binding pocket and interact with the V 1a receptor in a similar way while establishing its own network of molecular interactions. Because (i) 125 I-ZOTA displays an equivalent affinity for the human OTR and the human V 1a receptor, (ii) several residues involved in the binding of all classes of antagonists are conserved throughout the AVP/OT receptor family, and (iii) OTR and V 1a share a significant sequence identity in the upper part of TMD II, TMD III, TMD VI, and TMD VII as well as in the first extracellular loop, we propose that binding sites for 125 I-ZOTA in the OTR and V 1a receptor could be equivalent. However, to allow a more complete definition of the binding sites of the OTR for cyclic peptide antagonists such as 125 I-ZOTA or Atosiban (14, 15) and to generate meaningful information on receptor/antagonist interactions, it will be necessary to perform other photolabeling studies.
In conclusion, covalent attachment of 125 I-ZOTA to the upper part of TMD III of both the OTR and V 1a receptor is fully consistent with our previous 3D antagonist/V 1a receptor models. Taken together, these findings suggest once again as demonstrated previously that agonist and peptide antagonist binding pockets might be common to all receptor subtypes of the OT/AVP family and that specific residues can differentiate agonist versus antagonist binding in these receptors (29) . The delineation of a three-amino acid "contact domain" is a major step "en route" to a more detailed mapping of the molecular interactions between OT-related ligands and the OTR. The use of other photoactivatable antagonist ligands as well as molecular modeling of the OTR based on the recent 3D crystal structure of bovine rhodopsin (43) should be very helpful in the future for rationalizing the design of OT antagonists based on the receptor structure.
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